Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.55 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.51 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.45 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | S1PR2 | O95136 | 3/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3217766 | 0.79 | CXCR2 (0.73) | CXCR2ALDH1A1KDM4E | |
| SCHEMBL28466269 | 0.77 | HPGDS (0.72) | HPGDSS1PR3ALDH1A1GAASLC6A9 | |
| SCHEMBL3217701 | 0.74 | CA2 (0.56) | CXCR2ALDH1A1LMNAKDM4E | |
| SCHEMBL4458404 | 0.74 | HPGDS (0.79) | HPGDSS1PR3ALDH1A1GAASLC6A9 | |
| SCHEMBL3224615 | 0.72 | CXCR2 (0.54) | CXCR2ALDH1A1 | |
| SCHEMBL30530178 | 0.72 | SLC6A9 (0.71) | HPGDSS1PR3ALDH1A1GAASLC6A9 | |
| SCHEMBL3225114 | 0.71 | NPC1 (0.61) | CXCR2ALDH1A1GAALMNA | |
| SCHEMBL3220257 | 0.70 | CXCR2 (0.64) | CXCR2ALDH1A1 | |
| SCHEMBL5521051 | 0.70 | ALDH1A1 (0.76) | HPGDSALDH1A1GAASLC6A9SLC6A5 | |
| SCHEMBL28466273 | 0.70 | SLC6A9 (0.68) | HPGDSS1PR3GAASLC6A9SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063105-A1 | PHARMACEUTICAL USES AND SYNTHESIS OF NICOTINANILIDE-N-OXIDES | UCB SA (GB) | 2010-03-11 | — | — | US | disclosed |
| US-7141590-B2 | Pharmaceutical uses and synthesis of nicotinanilide-N-oxides | UCB SA (GB) | 2006-11-28 | — | — | US | disclosed |
| US-20050026965-A1 | Pharmaceutical uses and synthesis of nicotinanilide-N-oxides | DARWIN DISCOVERY LIMITED (GB) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063105-A1 | PHARMACEUTICAL USES AND SYNTHESIS OF NICOTINANILIDE-N-OXIDES | NNT, NAPRT, NNMT | HPGDS 488/4885CXCR2 1447/4885S1PR3 1698/4885 |
| US-20050026965-A1 | Pharmaceutical uses and synthesis of nicotinanilide-N-oxides | NNT, NAPRT, NNMT | HPGDS 488/4885CXCR2 1447/4885S1PR3 1698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.